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GlucagonGlucokinase activity is a major determinant of hepatic glucose metabolism and blood glucose homeostasis. Liver
glucokinase activity is regulated acutely by adaptive translocation between the nucleus and the cytoplasm
through binding and dissociation from its regulatory protein (GKRP) in the nucleus. Whilst the effect of glucose
on this mechanism iswell established, the role of hormones in regulating glucokinase location and its interaction
with binding proteins remains unsettled. Here we show that treatment of rat hepatocytes with 25 mM glucose
caused decreased binding of glucokinase to GKRP, translocation from the nucleus and increased binding to
6-phosphofructo 2-kinase/fructose 2,6 bisphosphatase-2 (PFK2/FBPase2) in the cytoplasm. Glucagon caused dis-
sociation of glucokinase from PFK2/FBPase2, concomitant with phosphorylation of PFK2/FBPase2 on Ser-32, up-
take of glucokinase into the nucleus and increased interaction with GKRP. Two novel glucagon receptor
antagonists attenuated the action of glucagon. This establishes an unequivocal role for hormonal control of glu-
cokinase translocation. Given that glucagon excess contributes to the pathogenesis of diabetes, glucagon may
play a role in the defect in glucokinase translocation and activity evident in animal models and human diabetes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The liver plays a vital role in blood glucose homeostasis by produc-
tion of glucose in the fasted state and efficient removal of glucose in
the post-prandial state in response to portal hyperglycaemia for storage
of glucose as glycogen or conversion to triacylglycerol [1]. Central to
this process is the responsiveness of the liver to the hormone glucagon
[1–3]. In normal physiology, glucagon is elevated in the post-absorptive
state and acts on the liver to stimulate glucose production via glycogen-
olysis and gluconeogenesis to maintain blood glucose homeostasismentation; cAMP, cyclic adeno-
ivated by cAMP; F26P2, fructose
ehydrogenase; GK, glucokinase;
hosphatase; mRFP, red fluores-
pO, desHis1Pro4Glu9-glucagon;
mide; Phos-a, glycogen phos-
ose 2,6-bisphosphatase-2; PKA,
w fluorescent protein
icine, 4th Floor William Leech
castle Upon Tyne NE2 4HH, UK.
.[1,2,4]. After a carbohydrate-containing meal, the elevation in insulin
suppresses glucagon secretion and thereby hepatic glucose production.
However, in type 2 diabetes the deficiency in insulin secretion results in
post-prandial hyperglucagonaemic and inadequate suppression of glu-
cose production [2,3].Whilst themechanisms involved in the regulation
of glycogenolysis and gluconeogenesis by glucagon have been well
characterised, the effects of glucagon excess on glucose utilisation
have not been fully elucidated.
Glucose metabolism by the liver is critically dependent on the activ-
ity of glucokinase, which catalyses the first-step in glucose metabolism
[5,6]. Two major mechanisms are involved in the regulation of glucoki-
nase activity: transcriptional mechanisms which account for chronic
changes in protein expression [6,7] and translocation from the nucleus
to the cytoplasm in response to portal hyperglycaemia or low concen-
trations of fructose,which accounts for the acute changes in postprandi-
al glucose disposal [5,8].
Sequestration of glucokinase in the hepatocyte nucleus at basal glu-
cose concentrations is regulated by binding to its inhibitory protein
(GKRP) [8–10]. Stimulation with elevated concentrations of glucose
(N10mM)ormicromolar concentrations of fructose or other precursors
of fructose 1-phosphate causes the dissociation of the glucokinase–
GKRP complex, allowing translocation of glucokinase from the nucleus
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gen synthesis [5,6,8]. Various lines of evidence implicate a potential
role for phosphofructo 2-kinase/fructose 2,6-bisphosphate (PFK2/
FBPase2) as a cytoplasmic binding partner of glucokinase [11,12].
Whilst a role for glucose in regulating glucose translocation is well
established [5,6], the role of hormones on glucokinase translocation
and its interaction with PFK2/FBPase2 remains unsettled [6,13]. Com-
pelling evidence for an over-riding role for glucagon excess in the path-
ogenesis of diabetes [3,14] and development of non-invasive methods
for estimating glucokinase activity in man based on the assumption
that glucokinase activity responds to glucose but not to hormones
[15,16], calls for a critical re-evaluation of the effect of glucagon on glu-
cokinase translocation and activity. The aims of this studywere to inves-
tigate whether glucagon acutely regulates glucokinase translocation
and binding to its binding partners GKRP and PFK2/FBPase2.
2. Materials and methods
2.1. Reagents
Proximity ligation assay reagents were from Olink (Uppsala,
Sweden); cAMP lysis buffer was from GE healthcare (Buckinghamshire,
UK); cAMP HTRF femto 2 kit was from Cisbio Bioassays (Codolet,
France); Synergi C-12 column was from Phenomonex (Cheshire, UK);
Site-directed mutagenesis kit was from Agilent Technologies (Berkshire,
UK);NE-PERnuclear extraction kitwas fromThermoScientific (Rockford,
IL); beta-actin antibodywas fromSigma-Aldrich (Poole, UK); Glucokinase
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA); GAPDH
antibody was from Hytest (Turku, Finland); Lamin A/C antibody was
from New England Biolabs (Hitchin, UK); GKRP antibody was from
Santa Cruz Biotechnology (Santa Cruz, CA); Total PFK2/FBPase2 antibody
was from Simone Baltrusch (University of Rostock, Germany); PFK2/
FBPase2 vector was from Alex Lange (University of Minnesota, Minne-
apolis, MN); Yellow fluorescent protein (YFP)-fragment vectors
were from Tom Kerppola (University of Michigan, Ann Arbor, MI).
2.2. Hepatocyte isolation/cell culture
Hepatocytes were isolated from male Wistar rats fed ad libitum [12]
obtained fromHarlan (Bicester, UK). Procedures conformed to Home Of-
fice regulations and were approved by the local ethics committee. COS1
cells were cultured as in [17]. Cells were seeded on gelatine-coated
coverslips for immunostaining, glass chambers for live-cell imaging or
24-well plates for enzyme activity, metabolite determination and flux
analysis. Hepatocytes were cultured overnight in MEM in the presence
of 10 nMdexamethasone and 10 nM insulin prior to treatment. All treat-
ments were performed in the absence of dexamethasone and insulin.
2.3. Immunostaining
Hepatocytemonolayerswere fixedwith 4% paraformaldehyde in PBS
and immunostained for glucokinase or PFK2/FBPase2 as in [12]. Nuclei
were counterstained using Hoechst 33342. Cells were imaged for
AlexaFluor-488 at excitation 465–495 nm; emission 515–555 nm and
Hoechst at excitation 330–380 nm; emission 420 nm using a Nikon
E400 microscope (×60). For method validation, 30 fields from 3 cover-
slips were imaged (700–950 cells). For subsequent measurements, 10
fields from2 coverslipswere imaged (80–100 cells). Fieldswere selected
at random based on Hoechst staining. The mean pixel intensity for the
nucleus and cytoplasm was analysed using Image ProPlus Software and
thenuclear-to-cytoplasmic (N/C) ratio calculated for each individual cell.
2.4. Glucagon antagonists
Novel glucagon receptor antagonists desHis1Pro4Glu9glucagon-amide
(PepO) and the acylated peptide desHis1Pro4Glu9Lys12(γ-glutamyl PAL)glucagon-amide (PepR)were produced by Fmoc solid phase peptide syn-
thesis by GL BiochemLtd. (Shanghai, China). All peptideswere N95% pure
as determined by reversed-phase HPLC analysis using acetonitrile gradi-
ent elution on a Synergi C-12 column (250 × 4.6 mm). Molecular masses
were checked by MALDI-TOF mass spectrometry using a Voyager-DE
Biospectrometry Workstation (PerSeptive Biosytems, Framingham, MA,
USA).
2.5. Proximity ligation assay (PLA)
Hepatocyte monolayers were fixed with 4% paraformaldehyde in
PBS and PLA performed as in [18] using antibodies against either gluco-
kinase and GKRP or glucokinase and PFK2/FBPase2. 20 fields from 2 to 3
coverslips/condition were selected at random based on Hoechst stain-
ing. The interaction was quantified using Blobfinder software based on
either the total number of dots in the nuclear or cytoplasmic compart-
ments or as total intensity of dots in the cell.
2.6. Enzyme activity, metabolite determination and glucose flux
Free, bound and total glucokinase activities were determined as in
[12]. Free and bound glucokinase activities are expressed as percentage
of total activity and total glucokinase activity expressed as mu/mg pro-
tein. Glucose phosphorylation and glycolysis were determined as in [12]
and lactate production as in [19] and are expressed as nmol/h/mg pro-
tein. Glycogen phosphorylase activity was determined as in [20] and is
expressed as mU/mg protein. For cAMP determination, cells were
lysed using cAMP lysis buffer and cAMP concentrations quantified
using the femto 2 HTRF kit as outlined by the manufacturer's instruc-
tions. cAMP concentrations are expressed as nmol/mg protein. Fructose
2,6-bisphosphate levels were determined as in [12] and are expressed
as fold change relative to the absence of glucagon.
2.7. mRNA determination
Glucose 6-phosphatase (G6pc)mRNA levelswere determined as de-
scribed in [7]. Relative mRNA levels were calculated by the Δ cycle
thresholdmethod andwere normalised to cyclophilinmRNA levels. Re-
sults were expressed relative to 5 mM glucose.
2.8. Bimolecular fluorescence complementation (BiFC)
Glucokinase-YN155, PFK2/FBPase2-YC155 and mRFP constructs
were generated and the BiFC assay performed as in [17]. The serine 32
residue on the PFK2 domainwasmutated to alanine (TCC to GCC) or as-
partate (TCC to GAC) using site-directed mutagenesis (S32A-fwd: CGG
CGA AGG GGC GCC TCC ATA CCA C; S32A-rev: GTG GTA TGG AGG CGC
CCC TTC GCC G; S32D-fwd: GCA ACG GCG AAG GGG CGA CTC CAT ACC
ACA GTT C; S32D-rev: GAA CTG TGG TAT GGA GTC GCC CCT TCG CCG
TGG C). Sequences were confirmed by DNA sequencing and protein
translation by western blotting. Constructs were co-expressed in COS1
cells and live-cell fluorescence visualised using a Nikon TE2000 fluores-
cence microscope (×100). Cells were imaged for yellow fluorescent
protein (YFP, Excitation 500/20 nm; Emission 535/30 nm), red fluores-
cent protein (mRFP, Excitation 575/25 nm; Emission 632/40 nm) and
Hoechst (Excitation 402/15 nm; Emission 455/20 nm). For quantifica-
tion, the number of cells expressing mRFP (transfection control) and
YFP (BiFC signal) was calculated (20-fields) and YFP-positive cells
expressed as a percentage of mRFP-positive cells.
2.9. Nuclear fractionation
Hepatocytes were fractionated into nuclear and cytoplasmic com-
partments using either the NE-PER nuclear extraction kit or as in [21].
An aliquot (30 μg) of cytoplasmic or nuclear protein was subjected to
SDS-PAGE following by western blotting.
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Immunoreactivity towards PFK2-(P) [12], GAPDH, Lamin A/C, total
PFK2 and β-actin was determined by SDS-PAGE using a 10% polyacryl-
amide gel and immunoblotting and was quantified using densitometry.
2.11. Statistical analysis
Results are expressed asmeans± s.e.m. for the number of cell prep-
arations and values compared using either the unpaired Student's t-test
or by one-way ANOVA followed by Bonferroni's test.
3. Results
3.1. The nuclear-to-cytoplasmic ratio is a more sensitive index of
glucokinase translocation than nuclear intensity
Whereas the effect of elevated glucose (25 mM vs. 5 mM) in
translocating glucokinase from the nucleus to the cytoplasm in hepato-
cytes is well established [12,13,22–24], the effect of glucagon remains
contentious [6,13,23,25] and an exclusive role for glucose as distinct
from hormone action is commonly inferred [15]. Possible explanations
for the discordance in hormonal control include differences in glucose
concentration [6,13,22,25] or whether data is analysed as the nuclear
to cytoplasmic (N/C) ratio calculated per cell [23,24] rather than the
average nuclear or cytoplasmic intensities [13,26]. To test for these pos-
sibilities, we determined the effects of glucagon on glucokinase translo-
cation at 5mMor 25mMglucose and analysed the data from N/C ratios
and also from nuclear or cytoplasmic intensities from N700 cells per
condition (Table 1). High glucose increased cytoplasmic intensity by
33% (7.9 ± 3.3 to 10.5 ± 3.7) and decreased both nuclear intensity
and N/C ratio by 30% and 48%, respectively (nuclear 62.2 ± 27.0 to
43.8 ± 14.4; N/C ratio 8.4 ± 3.3 to 4.4 ± 1.4) (Fig. 1A, Table 1). Gluca-
gon had no significant effect on glucokinase localization at 5 mM glu-
cose but attenuated the effects of 25 mM glucose, quantified as a 13%
decrease in cytoplasmic intensity (10.5 ± 3.7 to 9.1 ± 3.4), an 11% in-
crease in nuclear intensity (43.8 ± 14.4 to 48.8 ± 17.7) and a 32% in-
crease in the N/C ratio (4.4 ± 1.4 to 5.8 ± 2.3) (Fig. 1A, Table 1).
Fractional changes in response to 25 mM glucose or glucagon were
greater for the N/C ratio than for nuclear or cytoplasmic intensities
(Table 1) and accordingly the power calculations showed that a larger
sample size is required to detect significant differences in translocation
from nuclear or cytoplasmic intensities (nuclear: 234; cytoplasmic:
178) as opposed to N/C ratio (N/C ratio: 60) (Table 1). Based on these
power calculations, imaging of 80–100 nuclei/condition was necessary
to detect significant glucokinase translocation using the N/C ratio.
We next tested the effect of glucose concentration on the glucagon
response. Glucokinase translocation determined from the N/C ratio in-
creased significantly and progressively at glucose concentrations ofTable 1
Thenuclear-to-cytoplasmic ratio is amore sensitive index than nuclear intensity tomeasure gluco
orwith 100 nMglucagon for 1 h and glucokinase localisation determined using immunostaining.
is expressed as average± s.d.with the coefficient of variation shown in parentheses. Changes b
glucose are expressed as percentage change. The cell number required to reach a statistically signi
size calculations (two independent samples, desired power = 0.90).
Nuc
Average ± s.d. (CV) 5glc 62.
5glc + glucagon 57.
25glc 43.
25glc + glucagon 48.
Percentage change 25glc vs. 5glc −3
25glc + glucagon vs. 25glc +1
Cell number for p b 0.05 25glc vs. 5glc 47
25glc + glucagon vs. 25glc 23410 mM to 25 mM glucose relative to 5 mM (Fig. 1B). Glucagon partially
attenuated the effects of elevated glucose (10 to 25mM) but had no ef-
fect on glucokinase translocation at 5 mM glucose (Fig. 1B). Analysis of
this data based on individual nuclear or cytoplasmic intensities showed
greater variability compared to the N/C ratio (CV values: Nuclear = 5–
23%, Cytoplasmic= 16–30%; N/C= 2–13%) (Fig. 1B–D) and the chang-
es in glucokinase translocation in response to glucagon were not signif-
icant (Fig. 1C–D), in agreement with previous findings [13]. For the rest
of the study, glucokinase translocation was determined using the N/C
ratio, which offers a sensitive semi-quantitative method for the mea-
surement of glucokinase translocation.
3.2. Glucagon alters both glucokinase translocation and activity
To further confirm the effect of glucagon on glucokinase transloca-
tion, we measured free cytoplasmic glucokinase activity released from
digitonin-permeabilised hepatocytes [27] and the rate of detritiation
of [2-3H]glucose which is an approximate measure of glucose phos-
phorylation [28]. Stimulation with high glucose caused an increase in
free glucokinase activity (Fig. 1F) and a decrease in bound glucokinase
activity (Fig. 1G), representing translocationof glucokinase from thenu-
cleus to the cytoplasm. The glucose-induced changes in free and bound
glucokinase activity were significantly attenuated by glucagon (Fig. 1F,
G) consistent with the changes in N/C ratio (Fig. 1E). Due to the semi-
quantitative nature of the immunostaining technique, total glucokinase
concentration could not be accurately determined using absolute nucle-
ar plus cytoplasmic intensity levels. Therefore, the effect of glucagon on
cellular glucokinase content was assessed using total glucokinase activ-
ity. There was no change in total glucokinase activity, suggesting that
acute glucagon treatment alters glucokinase distribution rather than ac-
tivity/expression (Fig. 1H).
Inhibition of glucokinase translocation by glucagon was also ob-
served when hepatocytes were pre-equilibrated with 25 mM glucose
for 30min to allowmaximum translocation prior to glucagon challenge
(Fig. 1I, J). The effects of glucagon on glucokinase translocation at
25 mM glucose were associated with attenuation of metabolism of
[2-3H]glucose (Fig. 2K) and glycolysis, determined either radio-
chemically or from lactate formation (Fig. 2L, M). Fractional inhibition
ofmetabolism of [2-3H]glucosewas smaller than inhibition of glycolysis
(19% vs. 61–62%), consistent with additional effects of glucagon down-
stream of glucose phosphorylation [29].
3.3. The affinity for glucagon is similar for glucokinase translocation as for
established effects of the hormone
Wenext compared the effects of glucagon concentration on glucoki-
nase translocation with three established cellular responses to the hor-
mone: activation of glycogen phosphorylase, phosphorylation of PFK2/
FBPase2 at Ser-32 which determines the cellular concentration ofkinase translocation.Hepatocyteswere incubated at either 5mMor 25mMglucosewithout
Between 705 and 921 nuclei were imaged for each condition. Fluorescence (pixel intensity)
etween 25 mMglucose vs. 5 mM glucose and 25 mMglucose+ glucagon vs. 25 mM
ficant difference (p b 0.05) for the percentage changes shownwas determinedusing sample
lear intensity Cytoplasmic intensity N/C ratio
2 ± 27.0 (43) 7.9 ± 3.3 (42) 8.4 ± 3.3 (39)
3 ± 23.9 (42) 6.9 ± 2.6 (38) 8.8 ± 3.5 (40)
8 ± 14.4 (33) 10.5 ± 3.7 (35) 4.4 ± 1.4 (35)
8 ± 17.7 (36) 9.1 ± 3.4 (37) 5.8 ± 2.3 (40)
0 +33 −48
1 −13 +32
37 15
178 60
Fig. 1. Glucagon inhibits glucose-induced glucokinase translocation and glucose phosphorylation. (A) Hepatocytes were incubated at either 5 or 25 mM glucose without or with 100 nM
glucagon for 1 h and glucokinase localization determined using immunostaining. Between 705 and 921 nuclei were imaged for each condition. Images are representative of randomly
selected fields from 8 experiments. Scale bars: 20 μm. (B–D) Hepatocytes were incubated for 30 min at 5, 10, 15 or 25 mM glucose without or with 100 nM glucagon for determination
of glucokinase N/C ratio (B), nuclear intensity (C) and cytoplasmic intensity (D). (E–H) Hepatocytes were incubated for 30min at 5 vs. 25 mM glucose without or with 100 nM glucagon
for determination of glucokinaseN/C ratio (E), free glucokinase activity (F), boundglucokinase activity (G) or total glucokinase activity (H). (I–J) Hepatocyteswere incubated for 1 h at 5 vs.
25mM glucose followed by addition of 100 nM glucagon for a further 30 min for determination of N/C ratio (I) or free glucokinase activity (J). (K–M)Hepatocytes were incubated at 5 vs.
25 mM glucose with or without 100 nM glucagon for 1 h for determination of glucose phosphorylation (K), glycolysis (L) or lactate production (M). Means ± s.e.m. of 3–6 independent
experiments. *p b 0.05, **p b 0.01, ***p b 0.005 effect of glucose; #p b 0.05, ##p b 0.01, ###p b 0.005 effect of glucagon.
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and mRNA expression of glucose 6-phosphatase (G6pc) [30–33]. Stim-
ulation of hepatocytes with 1–100 nM glucagon caused an increase in
glycogen phosphorylase activity, G6pc mRNA levels, phosphorylationof PFK2/FBPase2 at Ser-32 and a decrease in glycolysis as determined
by lactate concentration (Fig. 2A–D), and an increase in the glucokinase
N/C ratio (Fig. 2E, F). All five parameters showed similar affinity for
glucagon with an EC50 between 1 and 10 nM (EC50 values: Phos-a =
Fig. 2.Glucokinase translocation has a similar affinity to glucagon as establishedmetabolic effects. Hepatocytes were incubated at 5 (B) or 25mM (A, C–F) glucosewith increasing concentrations of glucagon (0.01–100 nM) for (A) 5min for glycogen
phosphorylase activity, (B) 2 h forG6pcmRNA levels, (C) 30min for lactate concentration, (D) 10min for phosphorylation of PFK2/FBPase2 at Ser-32, and (E–F) 30min for glucokinaseN/C ratio. Data are plotted against glucagon concentration on a log
plot and the EC50 for glucagon calculated by non-linear regression analysis. Means ± s.e.m. of n = 4 from 2 independent experiments. Scale bars: 20 μm.
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Fig. 3. A novel glucagon antagonist inhibits glucagon-induced glucokinase translocation.
(A) Hepatocytes were incubated for 1 min without or with 10 μM desHis1Pro4Glu9-
glucagon (PepO) prior to the addition of 10 nM glucagon or 100 μM noradrenaline (NA)
for 30 min for the determination of glycogen phosphorylase activity. (B) Hepatocytes
were incubated for 1 minwithout or with 10 μM PepO prior to the addition of 10 nM glu-
cagon for 30min for thedetermination of cAMP levels. (C)Hepatocyteswere incubated for
1 min without or with 10 μM PepO prior to the addition of 10 nM glucagon for 30 min at
5 vs. 25 mM glucose for the determination of glucokinase N/C ratio. Means ± s.e.m.
of n = 6–8 from 3 independent experiments. **p b 0.01, ***p b 0.005 effect of glucose;
#p b 0.05, ##p b 0.01, ###p b 0.005 effect of glucagon or noradrenaline; ^^^p b 0.005 ef-
fect of glucagon antagonist.
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0.84 ± 0.19 nM; Glucokinase N/C ratio = 2.04 ± 0.29).3.4. Glucagon antagonists block glucagon-induced glucokinase movement
We next confirmed the specificity of the glucagon effect on glucoki-
nase translocation with novel glucagon receptor antagonists [34]. Pre-
incubation of hepatocytes with the novel antagonist desHis1Pro4Glu9-
glucagon (PepO) inhibited the activation of glycogen phosphorylase
by glucagon but not that by noradrenaline (Fig. 3A), confirming its spec-
ificity. PepO inhibited the glucagon-induced increase in cellular cAMP
and the translocation of glucokinase to the nucleus at elevated glucose
(Fig. 3B, C). Similar results were obtained for the acylated analogue
desHis1Pro4Glu9Lys12(γ-glutamyl PAL)glucagon-amide (results not
shown). These results confirm the involvement of glucagon signalling
in glucokinase translocation.Fig. 4.Glucagon regulates glucokinase translocation via a protein kinase A dependent mechanis
10 nMglucagon, 100 μMdibutyryl cAMP (Di-cAMP), 20 μMforskolin (FSK) or 100 μMSp-cAMP
for lactate concentration, (D) 10 min for phosphorylation of PFK2/FBPase2 at Ser-32, and (E–
incubated for 30minwith orwithout 10 μMH-89. Cells were then stimulatedwith 5 (H) or 25m
ylase activity, (H) 2 h for G6pc mRNA levels, (I) 30 min for lactate concentration, (J) 10 min f
cytoplasmic (N/C) ratio.Means ± s.e.m. of n = 4 from 2 independent experiments. #p b 0.0
^^^p b 0.005 effect of H-89. Scale bars: 20 μm.3.5. Glucagon regulates glucokinase translocation via a cAMP/PKA
dependent mechanism
To determine whether glucagon exerted its effects on glucokinase
translocation by a protein kinase A (PKA)-dependentmechanism, hepa-
tocytes were stimulated with PKA-selective or non-selective cAMP ana-
logues. Both selective (Sp-cAMP) and non-selective (forskolin and
dibutyryl-cAMP) cAMP analogues mimicked the effect of glucagon on
glycogen phosphorylase, G6pc mRNA expression, lactate production,
phosphorylation of PFK2/FBPase2 and glucokinase translocation
(Fig. 4A–F). Pre-treatment of hepatocytes with the PKA inhibitor H89
partially reversed the effect of glucagon on these parameters
(Fig. 4G–L), whilst the exchange protein directly activated by cAMP
(EPAC) inhibitor Brefeldin Ahadnoeffect (results not shown). These re-
sults suggest that glucagon regulates the localization of glucokinase by a
cAMP/PKA-dependent mechanism.
3.6. Glucagon disrupts the glucokinase–PFK2/FBPase2 complex
The accumulation of glucokinase in thehepatocyte nucleus is contin-
gent on binding to GKRP as supported by the exclusive cytoplasmic lo-
cation in GKRP KO models [9,10]. A candidate binding partner in the
cytoplasm is PFK2/FBPase2 [11,12]. We used a proximity ligation assay
(PLA) to quantify the interactions of glucokinase with GKRP and PFK2/
FBPase2. This assay uses primary antibodies raised against two candi-
date interacting proteins followed by secondary antibodies tagged
with complimentary oligonucleotides that can be ligated when
in close proximity. The product is then amplified for visualisation [18].
This enables objective quantification of two proximity-linked
proteins visualised as red dots (Fig. 5A, F). We first validated the tech-
nique from the interaction between glucokinase andGKRP. As expected,
at 5 mM glucose the interaction between glucokinase and GKRP was
predominately localised to the nuclear compartment (Fig. 5A, B). Stim-
ulationwith 25mMglucose caused a decrease in the glucokinase–GKRP
interaction in the total cell compartment and in the cytoplasm or nucle-
us (Fig. 5C–E). The effect of glucosewas reversed by the addition of glu-
cagon (Fig. 5C–E).
In contrast, the glucokinase–PFK2/FBPase2 complex predominately
localised to the cytoplasmic compartment (Fig. 5F, G). The staining pat-
tern indicates a peripheral location of the glucokinase–PFK2/FBPase2 in-
teraction close to the plasma membrane, consistent with previous
reports of glucokinase localization to this compartment [24]. No signal
was detected for isotype negative controls and overexpression of gluco-
kinase and PFK2/FBPase2 increased PLA signal intensity, confirming the
specificity of the signal (results not shown). The intensity of amplified
products (representing glucokinase–PFK2/FBPase2) was significantly
increased at 25mMcomparedwith 5mMglucose and this effectwas re-
versed by glucagon (Fig. 5H, J).
To further confirm the association between glucokinase and PFK2/
FBPase2, we used the bimolecular fluorescence complementation
(BiFC) assay in heterologous cells. This involves expression of the
two proteins of interest as fusion proteins with either the N-terminal
or C-terminal halves of YFP. If the two proteins associate, the non-
fluorescent N-terminal and C-terminal YFP fragments form a fluores-
cent complex [17]. COS1 cells transfected with glucokinase-YN155 and
PFK2/FBPase2-YC155 demonstrated formation of a BiFC complex
(Fig. 6A), confirming an interaction between glucokinase and PFK2/
FBPase2 in the cytoplasmic compartment. Formation of this complex
was slightly attenuated by dibutyryl cAMP (Fig. 6B). To determinem.(A–F). Hepatocytes were incubated at 5 (B) or 25mM glucose (A, C–F) with or without
for (A) 5min for glycogen phosphorylase activity, (B) 2 h for G6pcmRNA levels, (C) 30min
F) 30 min for glucokinase nuclear: cytoplasmic (N/C) ratio.(G–L). Hepatocytes were pre-
M glucose (G, I–L)with orwithout 10 nM glucagon for (G) 5min for glycogen phosphor-
or phosphorylation of PFK2/FBPase2 at Ser-32, and (K-L) 30 min for glucokinase nuclear:
5, ##p b 0.01, ###p b 0.005 effect of glucagon or cAMP analogue. ^p b 0.05, ^^p b 0.01,
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Fig. 6. cAMP disrupts the glucokinase–PFK2/FBPase2 complex. Cos 1 cells grown in glass chambers were transfected with 1 μg/well glucokinase-YN155 wild-type PFK2/FBPase2-YC155
(WT), Ser-32-Ala PFK2/FBPase2-YC155 (S32A) or Ser-32-Asp PFK2/FBPase2-YC155 (S32D) and 0.2 μg/well full-lengthmRFP protein for 24 h. Cells were then incubated at 25mMglucose
with or without 50 μM dibutyryl cAMP for 1 h for determination of the glucokinase–PFK2/FBPase2 interaction (yellow) using the BiFC assay. Means ± s.e.m. of 3–7 independent exper-
iments. #p b 0.05 effect of dibutyryl cAMP. ^p b 0.05 effect of mutant. Scale bars: 50 μm.
1131K.S. Cullen et al. / Biochimica et Biophysica Acta 1843 (2014) 1123–1134whether phosphorylation of PFK2/FBPase2 at Ser-32 [29,31] is involved
in regulating the glucokinase–PFK2/FBPase2 interaction, Ser-32 was
mutated to alanine (S32A) or aspartate (S32D). Wild-type and mutant
vectors (PFK2/FBPase2-YC155) were co-expressed with glucokinase-
YN155 in COS1 cells for BiFC analysis of the glucokinase–PFK2/FBPase2
interaction. The S32A and S32D mutants formed a complex with gluco-
kinase to the same extent as wild-type (Fig. 6C). Dibutyryl cAMP signif-
icantly attenuated complex formation for wild-type enzyme but had no
significant effect for the S32A mutant (Fig. 6D). These results support
involvement of Ser-32 phosphorylation in complex formation with
glucokinase.
3.7. Glucagon alters the subcellular location of PFK2/FBPase2 in hepatocytes
We next determined the time course of glucagon on glucokinase lo-
calization and its interaction with PFK2/FBPase2. Glucagon caused
phosphorylation of PFK2/FBPase2 at Ser-32within 5min (Fig. 7A), it de-
pleted its product fructose 2,6-bisphosphate during 5 to 20min (Fig. 7B)
and dissociated the glucokinase–PFK2/FBPase2 complex at 10 min
(Fig. 7C). A significant increase in translocation of glucokinase to the nu-
cleus was detectable after 20 to 30 min (Fig. 7D).
To determine the role of the glucokinase–PFK2/FBPase2 interaction
in the glucagon-induced uptake of glucokinase to the nucleus, the loca-
tion of PFK2/FBPase2 was determined. Previous studies have shown
that the ubiquitous isoform of PFK2/FBPase2 (PFKFB3) localises to the
nuclear compartment of cancer cells [35] but the location of the
liver isoform of PFK2/FBPase2 (PFKFB1) has not been investigated. By
immunostaining, the liver isoform of PFK2/FBPase2 can be detected inFig. 5. Glucagon disrupts the glucokinase–PFK2/FBPase2 complex. (A–B) Hepatocytes grown o
(PLA) used to detect the interaction between glucokinase and GKRP (red). Nuclei were staine
from 4 experiments. (B) The number of dots in the nuclear and cytoplasmic compartments wa
cubated at 5 or 25mMglucosewith orwithout 100 nMglucagon for 30min for determination of
quantified. (D) The total number of dots in the cytoplasm of each cell was quantified. (E) The t
5 mM glucose. (F–G) Hepatocytes were incubated at 25 mM glucose for 30min and PLA used t
resentative of 8 experiments. (G) The number of dots in the nuclear and cytoplasmic compartm
were incubated at 5 or 25 mM glucose with or without 100 nM glucagon for 30 min for determ
dots in each cell was quantified. (I) The total number of dots in the cytoplasm of each cell was
were normalised to 5 mM glucose. Means ± s.e.m. of 3–7 independent experiments. *p b 0.05
30 μm (F).both the cytoplasmic and nuclear compartments of hepatocytes
(Fig. 7E). However, the nuclear sequestration was much less pro-
nounced than for glucokinase (Fig. 1A), in that there was no predomi-
nance of PFK2/FBPase2 in the nucleus relative to the cytoplasm in any
of the incubation conditions. This and the large degree of heterogeneity
in PFK2/FBPase2 localization prevented reliable quantification of the
N/C ratio (Fig. 7E, F). Therefore, the location of PFK2/FBPase2was deter-
mined by subcellular fractionation and immunoblotting (Fig. 7G–J,
Supplementary Fig. 1). The purity of cytoplasmic and nuclear fractions
was confirmed using the cytoplasmic marker GAPDH (Fig. 7G) and the
nuclear marker Lamin A/C (Fig. 7H). PFK2/FBPase2 protein localised to
both nuclear and cytoplasmic compartments (Fig. 7I), consistent with
immunostaining (Fig. 7E). After treatment with glucagon, phosphory-
lated PFK2/FBPase2 at Ser-32 was detected in both the cytoplasmic
and nuclear fractions (Fig. 7J). Nuclear immunoreactivity to both phos-
phorylated PFK2/FBPase2 (Fig. 7J) and total PFK2/FBPase2 (Fig. 7I) de-
clined at 30 min. This demonstrates that the liver isoform of PFK2/
FBPase2 was present in the nucleus and it implicates movement of
PFK2/FBPase2 (phosphorylated form) between compartments in re-
sponse to glucagon.
4. Discussion
The importance of glucokinase translocation in determining the rate
of hepatic glucose disposal [5] and also the effect of glucose con-
centration on glucokinase translocation are well established from
studies in vitro or in vivo from several independent laboratories
[13,22–24,26,36–38]. However, the questionwhether this translocationn coverslips were incubated at 5 mM glucose for 30 min and the proximity ligation assay
d using Hoechst 33342 (blue). (A) Images are representative of randomly selected fields
s counted and results expressed as a percentage of total dots. (C–E) Hepatocytes were in-
the glucokinase–GKRP interaction using PLA. (C) The total intensity of dots in each cellwas
otal number of dots in the nucleus of each cell was quantified. Results were normalised to
o detect the interaction between glucokinase and PFK2/FBPase2 (red). (F) Images are rep-
ents was counted and results expressed as a percentage of total dots. (H–J) Hepatocytes
ination of the glucokinase–PFK2/FBPase2 interaction using PLA. (H) The total intensity of
quantified. (J) The total number of dots in the nucleus of each cell was quantified. Results
effect of glucose. #p b 0.05 effect of glucagon or dibutyryl cAMP. Scale bars: 20 μm (A) or
Fig. 7. Glucagon alters the subcellular location of PFK2/FBPase2 in hepatocytes. (A–F) Hepatocytes were incubated with 25 mM glucose with or without 100 nM glucagon for 5, 10, 20 or 30 min for the determination of phosphorylation of PFK2/
FBPase2 at Ser-32 by western blotting (A), fructose 2,6-bisphosphate (F26P2) concentration (B), the glucokinase–PFK2/FBPase2 interaction using PLA (C), glucokinase N/C ratio (D), PFK2/FBPase2 localization (E) and the PFK2/FBPase2 N/C ratio
(F). (G–J) Hepatocytes were incubated with 25 mM glucose with or without 100 nM glucagon for 5, 10 or 30 min. The subcellular locations of GAPDH (G), Lamin A/C (H), total PFK2/FBPase2 (I) and PFK2-Ser32(P) (J) were determined by western
blotting of nuclear and cytoplasmic fractions. Full size images of thewestern blots are shown in Supplementary Fig. 1.Means± s.e.m. of 4–7 independent experiments. #p b 0.05, ##p b 0.01, ###p b 0.005 effect of glucagon; ^p b 0.05 relative to 20min
time point. Scale bars: 20 μm.
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been less widely investigated and remains contentious [6,13,22,25].
This question is timely in view of the recognised role of hyper-
glucagonaemic in human diabetes [3], the potential therapeutic benefit
of glucagon antagonists for glycaemic control in diabetes [39], and cur-
rent methods for assessment of glucokinase activity based on the as-
sumption of exclusive control by glucose as opposed to hormones
[15,16].
A key limiting factor in the semi-quantitative analysis of changes in
the nuclear-to-cytoplasmic distribution of glucokinase is the large inter-
cellular heterogeneity of expression of glucokinase in both isolated
hepatocytes in vitro and also in liver in vivo [13,23,24,26,36]. This neces-
sitates the analysis of large numbers of cells. To date, twomethods have
been used for semi-quantitative analysis of glucokinase translocation:
either based on the determination of the ratio of cellular nuclear-to-
cytoplasmic (N/C) mean pixel intensity [23–25] or from the automated
nuclear or cytoplasmic intensity multiplied by the total cytoplasmic or
nuclear area estimated with an independent stain [13,26,37]. We
show in this study from the analysis of N/C ratio normalised per cell
that glucagon antagonises the effect of elevated glucose (10, 15 and
25 mM) on glucokinase translocation but has no significant effect at
basal glucose concentration (5 mM). We also confirm that the N/C
ratio is a more accurate assessment of translocation than the mean nu-
clear or cytoplasmic intensity based on cell outline methods consistent
with a previous study [24]. The failure to detect the effects of glucagon
on glucokinase translocation in recent studies [13] could be explained
by the low glucose concentration used, as well as the exclusive analysis
of global nuclear or cytoplasmic intensity. We show in this study that
the counter-regulatory effect of glucagon on glucose-induced transloca-
tion of glucokinase is abolished by glucagon receptor antagonists and
mimicked by non-metabolisable cyclic-AMP analogues.
We used the proximity ligation assay (PLA) for the quantification of
the protein–protein interaction of glucokinase with either GKRP or
PFK2/FBPase2. This assay enables the visualisation of two endogenously
expressed proteins that are in close proximity such that the antibody-
linked oligonucleotide tag can be ligated [18]. Using this assay we
show that at low glucose concentration the interaction between gluco-
kinase and GKRP occurred predominately (though not exclusively) in
the nucleus, consistent with the high nuclear to cytoplasmic ratio of
GKRP [24,40]. We also show that elevated glucose decreases the gluco-
kinase–GKRP interaction, with concomitant translocation of glucoki-
nase from the nuclear to cytoplasmic compartment and increased
binding between glucokinase and PFK2/FBPase2, an interaction that oc-
curs predominately (though not exclusively) in the cytoplasm. Glucoki-
nase has a bilobal structure linked by a flexible hinge [41] and exists as
an equilibrium of conformational states ranging from awide-open state
at low glucose concentration to a closed conformation at high glucose
[42,43]. Glucokinase binds to GKRP in the wide-open state [44,45] and
it binds to PFK2/FBPase2 most likely in the closed conformation [46].
The converse effects of elevated glucose on the interaction of glucoki-
nase with GKRP and PFK2/FBPase2 are therefore consistent with the ex-
pected binding to these two proteins. Interestingly, glucagon caused
complete reversal of the effect of elevated glucose on both the glucoki-
nase–GKRP and glucokinase–PFK2/FBPase2 interactions (Fig. 5) despite
causing only partial reversal of the effect of glucose on the distribution
of glucokinase between the cytoplasm and nucleus (Fig. 1). It is note-
worthy that whilst immunostaining provides a global measure of the
distribution of glucokinase between the nuclear and cytoplasmic com-
partments, the PLA assay is ameasure of two proteins in close proximity
and in an orientation that allows the antibody tags to form a complex.
Therefore, the signal detected by the PLA assay most likely represents
a subset of the glucokinase molecules. In principle, glucokinase may
bind simultaneously to more than one protein. For example, shuttling
between the cytoplasm and nucleus may involve interaction with
additional shuttling proteins, which may mask the epitopes to PFK2/
FBPase2 or GKRP or alternatively force the complex into a more or lessfavourable orientation for ligation of the complementary tags. The
marked effect of glucagon in reversing the effects of elevated glucose
on both the glucokinase–PFK2/FBPase2 interaction and the glucoki-
nase–GKRP interaction is compelling evidence for hormonal control of
glucokinase shuttling through interactions with these partners.
Glucagon regulates the transition from hepatic glucose utilisation in
the absorptive state to glucagon production in the post-absorptive state
by acute stimulation of glycogenolysis and inhibition of glycolysis [1].
An important component of this response is the phosphorylation of
liver PFK2/FBPase2 at Ser-32 [25,29], which increases the bisphosphatase
to kinase ratio of the bifunctional enzyme leading to depletion of fructose
2,6-bisphosphate and inhibition of glycolysis and elevation in gluconeo-
genesis [25]. Here we show that the phosphorylated form of PFK2/
FBPase2 is found in the nucleus as well as the cytoplasm and that gluca-
gon alters the amount of phosphorylated PFK2/FBPase2 in the nucleus.
This implicates a potential role for PFK2/FBPase2 in the glucagon-
induced changes in the subcellular location of glucokinase. We propose
the followingmodel: glucagon via cAMP/PKA-dependent signalling alters
the glucokinase–PFK2/FBPase2 interaction by a mechanism that may in-
volve phosphorylation of PFK2/FBPase2 at Ser-32. These changes enable
movement of glucokinase to the nuclear compartment, either in complex
with PFK2/FBPase2 or GKRP or both proteins. The BiFC data supports the
existence of a multi-protein complex since the cAMP analogue signifi-
cantly attenuated but did not block the formation of the glucokinase–
PFK2/FBPase2 complex. The BiFC assay is carried out in a heterologous
cell system lacking GKRP and thus measures the interaction of glucoki-
nase and PFK2/FBPase2 independently of GKRP, which is essential for
translocation and sequestration of glucokinase to the nucleus in hepato-
cytes [47,48]. The failure of the cAMP analogue to block the interaction of
glucokinase with PFK2/FBPase2 in the BiFC assay indicates that phos-
phorylation does not prevent formation of the complex. One possibility
that remains to be tested is that phosphorylation may favour formation
of a multi-protein complex with GKRP enabling translocation of glucoki-
nase to the nucleus. Furtherwork testing for a trimer complex is required
to investigate this possibility.
Several studies have reported that translocation of glucokinase in re-
sponse to glucose is impaired in animal models of type 2 diabetes
[25,37,38,49,50]. The present evidence that glucagon antagonises the
action of elevated glucose on translocation of glucokinase from the nu-
cleus and binding to PFK2/FBPase2 in the cytoplasm adds a new per-
spective to the acute control of glucokinase activity and shows that
absolute or relative glucagon excess as occurs in diabetes [3] is most
likely a contributing factor to the defective glucokinase translocation
in animal models of diabetes [25,37,38,49,50].
Supplementary data to this article can be found online at http://dx.
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